Zylox-tonbridge and avinger forge strategic partnership to expand disruptive oct solutions for peripheral vascular interventions

Hangzhou, china, march 7, 2024 /prnewswire/ -- zylox-tonbridge (2190.hk, "the company"), a leading medical device company in the peripheral and neurovascular interventional market in china, today announced a new strategic partnership with avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. this partnership includes an exclusive right to zylox-tonbridge to localize, manufacture, and commercialize the entire product family developed by avinger in greater china (including mainland china, hong kong, taiwan, and macau), and a technology transfer agreement to leverage zylox-tonbridge cost-efficient manufacturing capacity to support avinger's global sales outside of greater china.
AVGR Ratings Summary
AVGR Quant Ranking